A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Completed · Phase 4

Conditions studied: Glaucoma

In brief

Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.

Key facts

Study ID

NCT00348062

Run by

Innovative Medical

Last updated by the study team

2007-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• · Male or female > 18 years of age
• No prior use of bimatoprost
• Diagnosis of open-angle glaucoma or ocular hypertension
• Ability to provide informed consent and likely to complete all study visits

You may not qualify if…

• · Known contraindication to bimatoprost
• Uncontrolled systemic disease
• Active ocular disease other than glaucoma or ocular hypertension
• Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
• History of intraocular surgery within the last 3 months

Where it is running

• Dr. Noecker — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.